News and Press Releases
Press releases
Theralase® Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseTheralase Medical and Scientific Advisory Board concluded that the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has met its objectives and unanimously voted for the early termination of the Study...
Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleasePatient Five Shows No Clinical Evidence or Presence of NMIBC at 90 Day Cystoscopy Analysis Patient Six Shows No Clinical Evidence or Presence of NMIBC to Date Toronto, Ontario – April 16, 2018 Theralase Technologies Inc. (“Theralas...
Theralase® Increases Revenue 22% for 2017 Financial Statements
Press ReleaseToronto, Ontario – April 30, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleasePatient Six Demonstrates No Clinical Evidence of NMIBC at 90 Day Cystoscopy Analysis Toronto, Ontario – May 17, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage phar...
Theralase® Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
Press ReleaseToronto, Ontario – March 27, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Theralase® Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
Press ReleaseToronto, Ontario – March 15, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Rutherrin® Technology Granted Allowance for Canadian Patent
Press ReleaseToronto, Ontario – March 7, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Advances Anti-Cancer Technology in Destruction of Human Lung Cancer
Press ReleaseToronto, Ontario – March 5, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Announces Settlement Agreement with Ontario Securities Commission
Press ReleaseToronto, Ontario – February 26, 2018 Theralase® Technologies Inc. (the “Company”) (TSXV: TLT) (OTCQX: TLTFF) announced today that the Company and Roger Dumoulin-White, former Chairman, President and Chief Executive Officer, have e...
Theralase® Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer
Press ReleaseToronto, Ontario – February 9, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTCQX), a clinical stage pharmaceutical company dedicated to the research and development of patented, light a...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
